Table 4.
Univariate prognostic analyses.
| Parameters | HR | DFS 95% CI | P | HR | OS 95% CI | P |
|---|---|---|---|---|---|---|
| Age | ||||||
| ≤ 60 years | 1 | 1 | ||||
| > 60 years | 2.702 | 1.404–5.200 | 0.003 | 2.056 | 1.093–3.868 | 0.025 |
| Histology | 0.009 | 0.039 | ||||
| Endometrioid carcinoma grade 3 | 1 | 1 | ||||
| Serous carcinoma | 2.533 | 1.177–5.453 | 0.017 | 1.286 | 0.644–2.567 | 0.476 |
| Clear cell carcinoma | 0.862 | 0.265–2.801 | 0.805 | 0.536 | 0.176–1.629 | 0.272 |
| Carcinosarcoma | 4.895 | 1.505–15.921 | 0.008 | 2.675 | 0.879–8.136 | 0.083 |
| Neuroendocrine | 8.488 | 1.058–68.131 | 0.044 | 10.318 | 1.304–81.642 | 0.027 |
| Myometrial invasion | ||||||
| Superficial | 1 | 1 | ||||
| Deep | 2.640 | 1.414–4.929 | 0.002 | 2.378 | 1.275–4.437 | 0.006 |
| Lymph node metastasis | ||||||
| Absent | 1 | 1 | ||||
| Present | 2.833 | 1.277–6.284 | 0.010 | 1.957 | 0.833–4.599 | 0.124 |
| FIGO stage | < 0.001 | < 0.001 | ||||
| I | 1 | 1 | ||||
| II | 2.108 | 0.633–7.016 | 0.224 | 1.633 | 0.518–5.141 | 0.402 |
| III | 7.085 | 3.216–15.609 | < 0.001 | 4.050 | 1.966–8.345 | < 0.001 |
| IV | 3.930 | 0.828–18.662 | 0.085 | 7.005 | 2.194–22.361 | 0.001 |
| CA125 (U/mL) at primary diagnosis | ||||||
| ≤ 46.50 | 1 | 1 | ||||
| > 46.50 | 3.444 | 1.804–6.573 | < 0.001 | 2.776 | 1.420–5.427 | 0.003 |
| HE4 (pmol/L) at primary diagnosis | ||||||
| ≤ 89.50 | 1 | 1 | ||||
| > 89.50 | 3.749 | 1.937–7.259 | < 0.001 | 3.176 | 1.607–6.279 | 0.001 |
| CA125 (U/mL) at recurrence | ||||||
| ≤ 32.45 | 1 | 1 | ||||
| > 32.45 | 15.507 | 7.112–33.814 | < 0.001 | 8.059 | 3.922–16.563 | < 0.001 |
| HE4 (pmol/L) at recurrence | ||||||
| ≤ 92.50 | 1 | 1 | ||||
| > 92.50 | 12.317 | 5.988–25.337 | < 0.001 | 7.042 | 3.395–14.607 | < 0.001 |
HR hazard ratio, CI confidence interval.